ACU-193 is a monoclonal antibody commercialized by Acumen Pharmaceuticals, with a leading Phase I program in Alzheimer’s Disease. According to Globaldata, it is involved in 2 clinical trials, of which 1 is ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of ACU-193’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for ACU-193 is expected to reach an annual total of $7 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

ACU-193 Overview

ACU-193 is under development for the treatment of Alzheimer's disease and mild cognitive impairment due to AD and mild dementia due to Alzheimer's disease. It is a fully-humanized, IgG2 murine monoclonal antibody capable of selective binding to soluble abeta oligomers/ADDLs (amyloid precursor protein). It is administered through the intravenous route as infusion. ADDLs are highly ordered aggregates of amyloid-beta 1-42 peptides. It is developed based on ADDL-Select technology.

Acumen Pharmaceuticals Overview

Acumen Pharmaceuticals (Acumen) is a developer of therapeutics and diagnostics for the treatment of Alzheimer’s disease and related neurodegenerative conditions. The company discovers and develops ADDL-Select antibodies that target soluble amyloid-beta oligomers that inhibit nerve function, trigger early memory deficits, initiate nerve cell degeneration and downstream pathological events in Alzheimer’s. Its lead candidate include ACU-193, an anti-ADDL antibody which is in preclinical development stage. Acumen also uses an ultra-high sensitivity assay to measure soluble amyloid-beta oligomer levels in the cerebrospinal fluid in patients to be enrolled in clinical trials.The company owns intellectual property for soluble A-beta oligomers, ADDLs and related therapeutics and diagnostics. Acumen is headquartered in Livermore, California, the US.

The operating loss of the company was US$19.6 million in FY2021, compared to an operating loss of US$7.9 million in FY2020. The net loss of the company was US$100.6 million in FY2021, compared to a net loss of US$7.3 million in FY2020.

For a complete picture of ACU-193’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.